Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) EBITDA Margin: 2013-2025

Historic EBITDA Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to 13.20%.

  • Amphastar Pharmaceuticals' EBITDA Margin fell 1664.00% to 13.20% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.73%, marking a year-over-year decrease of 888.00%. This contributed to the annual value of 28.06% for FY2024, which is 251.00% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' EBITDA Margin stood at 13.20%, which was down 45.43% from 24.19% recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year EBITDA Margin high stood at 40.25% for Q3 2023, and its period low was 10.00% during Q1 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' EBITDA Margin had a median value of 25.32% in 2023 and averaged 26.48%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first spiked by 2,092bps in 2023, then slumped by 1,664bps in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBITDA Margin (Quarterly) stood at 20.06% in 2021, then skyrocketed by 796bps to 28.02% in 2022, then spiked by 229bps to 30.31% in 2023, then tumbled by 611bps to 24.20% in 2024, then tumbled by 1,664bps to 13.20% in 2025.
  • Its last three reported values are 13.20% in Q3 2025, 24.19% for Q2 2025, and 21.87% during Q1 2025.